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ABSTRACT
The objective of this study was to identify risk factors for bacteremia by extended-spectrum 
β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae. Retrospective case-
control study performed in a 450-bed acute care academic tertiary hospital in Barcelona, Spain. 
Cases included 53 patients with ESBL-producing E. coli or K. pneumoniae bacteremia, and 159 
controls with non-ESBL-producing E. coli or K. pneumoniae bacteremia. Controls were matched 
in a 3:1 ratio to case patients according to species of infecting organism, age, and severity of 
illness in the 24-48h before blood sample collection for culture calculated by the Simplified Acute 
Physiology Score (SAPS II) system. Previous antimicrobials were more frequently administered to 
cases than to controls (56.5% vs 17%, p < 0.001). Binary logistic regression showed that the number 
(> 2) of different families of antimicrobials received within 90 days before bloodstream infection was 
the only predictor of ESBL-producing E. coli or K. pneumoniae in blood culture (OR = 2.29, 95% 
CI 1.35-3.88, p = 0.002). Conclusion: Previous use of different families of antimicrobials (more than 
two) in patients with bloodstream infection caused by E. coli or K. pneumoniae increased the risk for 
ESBL-producing strains. 
Keywords: bacteremia; β-lactamases; risk factors.
An increase of extended-spectrum β-lactamase 
(ESBL)-producing organisms isolated from 
blood cultures has emerged in recent years.1 
Despite the fact that previous use of antimi-
crobial therapy has been frequently associated 
with the identification of ESBL-producing or-
ganisms, there is a large heterogeneity in the 
obtained results in different studies, which may 
be partially attributed to methodological dif-
ferences. A retrospective case-control study in 
patients with bloodstream infections caused by 
ESBL-producing Escherichia coli and Klebsiella 
pneumoniae was carried out to identify risk 
factors associated with these ESBL -producing 
organisms.
The investigation was conducted at Hospi-
tal Universitario del Mar, a 450-bed acute care 
academic tertiary hospital located in Barce-
lona, Spain. A matched case-control study was 
designed. All case and control patients were 
retrospectively identified through the blood-
stream infection database of the hospital In-
fection Control Program. All patients with 
bloodstream infection for whom culture results 
were positive for E. coli or K. pneumoniae from 
January 2000 to December 2006 were eligible 
for inclusion in the study. Designation as a case 
patient or a control patient was based solely on 
whether the infecting organism was found to 
demonstrate ESBL resistance or not.
Each patient was included as a case patient 
only once. If ESBL-producing E. coli or K. pneu-
moniae was isolated on multiple occasions, 
only the first episode of infection was consid-
ered. Controls were identified among hospital-
ized patients with bloodstream infection who 
were infected with the non-ESBL-producing E. 
coli or K. pneumoniae during the same period. 
Controls were matched in a 3:1 ratio to case 
patients according to the following variables: 
species of infecting organism, age, and sever-
ity of illness in the 24-48h before blood sample 
collection for culture calculated by the Simpli-
fied Acute Physiology Score (SAPS II) system.2 
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For missing values, a replacement was calculated using the 
mean value of the result preceding, and the result after, the 
missing one.3
In those patients in whom the sample was drawn for 
blood culture on hospital admission, the SAPS II score on 
admission was considered.
Nosocomial acquisition of infection was considered 
when the infection occurred > 48h after admission to the 
hospital, while community-acquired bacteremia when it 
occurred < 48 h after admission to the hospital. Acquisition 
of infection in the outpatient setting was also considered 
in patients with bloodstream infection secondary to diag-
nostic or therapeutic procedures carried out in the outpa-
tient setting, outpatients who were carriers of urinary or 
intravenous catheters, bloodstream infections in chronic 
hemodialysis and peritoneal dialysis patients, and bactere-
mias occurring in patients admitted to nursing homes or 
long-term care facilities. Infection that occurred > 48h after 
admission to the intensive care unit (ICU) was defined as 
ICU-acquired bacteremia.
Potential risk factors for ESBL-producing E. coli or 
K. pneumoniae infection were ascertained by abstract-
ing medical records. Data obtained included age, sex, 
underlying illness, severity of illness on hospital admission 
and 24-48h before blood sampling for culture both calcu-
lated by the SAPS II score, salient features of the patient’s 
care, invasive procedures performed within 30 days prior 
to the episode of bacteremia, organisms isolated within 
90 days prior to the episode of bacteremia, site of acquisi-
tion of infection, site of infection, antimicrobial sensitivity 
pattern of strains isolated in blood culture, antimicrobials 
administered within 90 days prior to the episode of bacte-
remia, immunosuppressive therapy, empirical and definitive 
antimicrobials administered for the treatment of bactere-
mia, and crude mortality. Severe neutropenia was defined 
as absolute neutrophil count < 500 neutrophils/μL and 
absolute neutropenia as < 100 neutrophils/μL.4 Immunosup-
pressive therapy included the administration of corticoids, 
cytostatic agents and/or immunosuppressants within 30 days 
prior to the episode of bacteremia. Antimicrobial treatment 
was defined as adequate when an active antimicrobial agent 
(as determined by in vitro susceptibility testing) was pre-
scribed at appropriate doses, at appropriate dosing intervals, 
and by the correct route5 and with the capacity to achieve 
adequate concentrations in the infectious focus. Antibiotic 
treatment was defined as inappropriate when the aforemen-
tioned definition was not met.
Identification of strains of E. coli and K. pneumoniae was 
determined by the Vitek system (bioMérieux). According 
to the Clinical and Laboratory Standards Institute (CLSI), 
sensitivity of the isolated strains against one of the following 
antimicrobials was assessed: cefotaxime, ceftriaxone, ceftazi-
dime, cefpodoxime, or aztreonam was initially determined 
using a disk diffusion method or a broth microdilution as-
say based on the minimal inhibitory concentration (MIC).6 
If results of this first test were positive, a phenotypic con-
firmatory test with cefotaxime and ceftazidime alone and 
in combination with clavulanic acid using a disk diffusion 
method or a microdilution assay was performed. 
The presence of ESBL-producing organisms was 
confirmed by an increase of > 5 mm in inhibition halo of 
cefotaxime or ceftazidime after the addition of clavulanic 
acid by the disk diffusion method, and by a greater than 
three-fold reduction in the MICs of either ceftazidime or ce-
fotaxime in the microdilution assay.
Data were analyzed using the Statistical Package for the 
Social Sciences (SPSS, version 12.0). Variables related to 
ESBL-producing E. coli or K. pneumoniae in the univariate 
analysis for which a p-value < 0.15 was found in the com-
parison of cases and controls were considered for inclusion 
in a binary logistic regression model, with the exception of 
those presenting a high number of missing data. In addition, 
certain key variables based on a priori hypothesis or empiri-
cal knowledge believed to be related to the dependent vari-
able were also included in the model. A backward stepwise 
selection procedure was used with the likelihood ratio test as 
the criterion for determining variables to be excluded (vari-
ation < 15%). The strength of the association between the 
explanatory variables in the model and the dependent vari-
able was established by odds ratios (ORs) and the 95% confi-
dence intervals (CIs). The hypothesis that the logistic model 
adequately fitted the data was tested by means of the good-
ness-of-fit χ2 test and the predictive capacity by the receiver 
operating characteristics (ROC) curve. Survival curves in 
cases and controls from isolation of ESBL-producing and 
non-ESBL-producing E. coli or K. pneumoniae until death 
and from hospital admission until death were obtained by 
the Kaplan Meier method.
During the study period, 4,172 episodes of blood-
stream infections were identified, 1,218 (29.2%) of which 
were caused by E. coli and 226 (5.4%) by K. pneumoniae. 
ESBL-producing E. coli or K. pneumoniae were identified in 
42 and 11 case patients, respectively. Controls included 126 
episodes of bloodstream infection caused by E. coli and 33 
by K. pneumoniae. There were statistically significant dif-
ferences between cases and controls in the percentage of 
males, patients with malignant hematologic diseases, urgent 
hospital admission, ICU admission, length of ICU stay, 
mechanical ventilation, invasive procedure, days with cath-
eter in place, hemodialysis, use of corticoids and cytostatic 
agents, and length of hospital stay. Moreover, community-
acquired bacteremia was significantly more frequent among 
controls and nosocomial bloodstream infection among cases 
(Table 1). Primary bacteremia was considered in 6 (11,3%) 
cases and in 9 (5.7%) controls, and secondary bacteremia in 
47 (88.7%) cases and in 150 (94.3%) controls. Main sources 
Quirante, Cerrato, Pardos
Braz J Infect Dis 2011; 15(4):370-376
BJID-4-JUN ARTE FINAL.indd   371 28/07/11   13:31
372
Table 1. Demographic, clinical and microbiological characteristics of patients with bloodstream infection due 
to ESBL-producing E. coli or K. pneumoniae (cases) and non- ESBL-producing E. coli or K. pneumoniae (controls)
Data Cases (n = 53) Controls (n = 159) p-value
Men 36 (67.9)* 71 (44.7) 0.004
Age, years, mean (95% CI) 69.1 (64.6-73.6) 71.1 (64.6-73.6) 0.416
Acquisition of infection   < 0.001
 Hospital 25 (47.2) 35 (22.0) 
 Community 19 (35.8) 117 (73.6) 
 ICU 9 (17) 7 (4.4) 
 Hospital admission in the previous 3 months 3 (5.7) 15 (9.4) 0.571
Clinical characteristics   
 Solid tumor 14 (26.4) 39 (24.5) 0.855
 Malignant hematologic disease 9 (17.0) 10 (6.3) 0.026
 Hypertension 22 (41.5) 78 (49.1) 0.427
 Dyslipidemia 4 (7.5) 27 (17) 0.117
 Diabetes mellitus 16 (30.2) 34 (21.4) 0.196
 Chronic obstructive pulmonary disease 8 (15.1) 20 (12.6) 0.643
 Chronic heart failure 1 (1.9) 12 (7.5) 0.193
 Renal failure 11 (20.8) 21 (13.2) 0.190
 Liver dysfunction 3 (5.7) 4 (2.5) 0.370
 Hepatitis C virus (HCV) infection 2 (3.8) 13 (8.2) 0.279
 HIV infection 2 (3.8) 3 (1.9) 0.433
 Renal transplantation 2 (3.8) 2 (1.3) 0.261
SAPS II score, mean (95% CI)   
 On admission 30.5 (28.2-32.7) 28.8 (27.2-30.4) 0.153
 24-48 h before blood sampling 32 (29.6-34.4) 31.2 (28.8-33.2) 0.318
 Urgent hospital admission 40 (75.5) 148 (93.1) 0.002
 Infection-related hospital admission 24 (45.3) 86 (54.1) 0.272
Clinical data before identification of  
causative pathogen in blood culture   
 ICU admission 9 (17.0) 7 (4.4) 0.005
 ICU stay, days, mean (95% CI) 28.1 (16.8-39.5) 13.4 (6.8-20.1) 0.020
 Mechanical ventilation 13 (24.5) 10 (6.3) 0.001
 Days on mechanical ventilation, mean (95% CI) 22.7 (10.8-34.5) 10.5 (2.3-18.7) 0.148
 Days with catheter in place, mean (95% CI) 22.7 (10.8-34.5) 10.5 (2.3-18.7) 0.148
 Carrier of urinary catheter 9 (17.0) 7 (4.4) 0.005
 Carrier of feeding tube 28.1 (16.8-39.5) 13.4 (6.8-20.1) 0.020
 Invasive procedure 13 (24.5) 10 (6.3) 0.001
 Hemodialysis 22.7 (10.8-34.5) 10.5 (2.3-18.7) 0.148
 Corticoids 22.7 (10.8-34.5) 10.5 (2.3-18.7) 0.148
 Cytostatic agents 10 (18.9) 11 (6.9) 0.017
 Immunosuppressants 2 (3.8) 3 (1.9) 0.601
 Neutropenia ≤ 500 neutrophils/µL 5 (9.4) 9 (5.7) 0.346
 Neutropenia ≤ 100 neutrophils/µL 5 (9.4) 8 (5.0) 0.319
 Length hospital stay, days, mean (95% CI) 18.8 (12.8-24.8) 4.9 (3.6-6.1) < 0.001
Microbiological data before identification  
of causative pathogen in blood culture   
 Previous culture performed 36 (67.9) 26 (16.3) < 0.001
 ESBL-producing E. coli or K. pneumoniae 8/36 (22.2) 1/26 (3.8) 0.009
* Data as numbers and percentages in parenthesis unless otherwise stated.
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of infection in secondary bacteraemia were urinary tract 
infection [19 (40.4%) vs 94 (62.7%)], gastrointestinal 
tract infection [6 (12.8%) vs 27 (18,0%)], intravascular de-
vice-related infection [9 (19.1%) vs 3 (3.0%)], pneumonia 
[3 (6.4%) vs 8 (5.3%)], surgical infection [4 (8.5%) vs 
2 (1.3%)], respiratory infection (excluding pneumonia) 
[1 (2.1%) vs 4 (2.7%)], and skin and soft tissue infection [0 
(0%) vs 1 (0.7%)].
On the other hand, isolation of ESBL-producing E. coli or 
K. pneumoniae within 90 days prior to the index episode was 
significantly more frequent among cases (22.2%, 8/36) than con-
trols (3.8%, 1/26) (p = 0.009). Antimicrobials prior to isolation of 
the causative pathogen in blood cultures were more frequently 
administered to cases than controls (56.5% vs 17%, p < 0.001).
Details of antimicrobial treatment are shown in Table 2.
In the binary logistic regression model adjusted by 
SAPS II on hospital admission, the number of different 
families of antimicrobials received within 90 days before 
the episode of bloodstream infection was the only signifi-
cant factor associated with identification of ESBL-produc-
ing E. coli or K. pneumoniae in blood culture (OR = 2.29, 
95% CI 1.35-3.88, p = 0.002). In addition, when the num-
ber of different families of antimicrobials was categorized 
as ≤ 2 and > 2 (the cut point that allowed a more homoge-
neous distribution of patients in the different categories), 
the use of > 2 different families of antimicrobials in the 
previous 90 days was the only variable independently as-
sociated with identification of ESBL-producing E. coli or 
K. pneumoniae in blood culture (OR = 12.50, 95% CI 2.50-
62.42, p = 0.002). The goodness-of-fit test did not reach 
statistical significance (p = 0.390). The area under the ROC 
curve was 0.718 (95% CI 0.58-0.85, p = 0.005).
A total of 47 patients who did not receive empirical anti-
microbials or in whom empirical treatment was inadequate, 
were then treated with adequate definitive antimicrobial 
therapy. Of these patients, 24 (51.1%) were cases and 23 
(48.9%) were controls. 
The mean number of hours until the use of adequate de-
Table 2. Antimicrobial treatment administered to patients with bloodstream infection due to ESBL-producing 
E. coli or K. pneumoniae (cases) and non-ESBL-producing E. coli or K. pneumoniae (controls) within 90 days 
before isolation of pathogen in blood culture
Data  Cases (n = 53) Controls (n = 159) p-value
All patients   
 Types of antimicrobials, mean (95% CI)  1.9 (1.3-2.6)* 0.3 (0.2-0.4) < 0.001
 Different antimicrobial families, mean (95% CI) 1.7 (1.1-2.3) 0.3 (0.2-0.3) < 0.001
Patients with previous antibiotic treatment   
 Number of patients 30 (56.6) 27 (17) < 0.001
 Days on antimicrobial treatment, mean (95% CI) 38.9 (25.9-51.8) 13.7 (9.8-17.6) 0.002
 Types of antimicrobials, mean (95% CI)  3.4 (2.5-4.3) 1.6 (1.3-1.8) 0.001
 Antimicrobial families, mean (95% CI) 3.1 (2.3-3.8) 1.5 (1.2-1.8) 0.003
 Different antimicrobial families, mean (95% CI) 3.0 (2.3-3.7) 1.4 (1.2-1.7) 0.002
 Aminoglycosides 8 (26.7) 2 (7.4) 0.083
 Carbapenems 4 (13.3) 3 (11.1) 1.000
 Cephalosporins 16 (53.3) 7 (25.9) 0.058
 Colistin 2 (6.7) 0 0.492
 Glycopeptides 12 (40.0) 2 (7.4) 0.005
 Lincosamides 0 1 (3.7) 0.474
 Macrolides 3 (10.0) 0 0.239
 Nitroimidazoles 5 (16.7) 1 (3.7) 0.197
 Oxazolidinones 4 (13.3) 0 0.114
 Penicillins 16 (53.3) 15 (55.6) 1.000
 Quinolones 14 (46.7) 7 (25.9) 0.169
 Sulfamides 4 (13.3) 1 (3.7) 0.356
 Tuberculostatic agents 2 (6.7) 0 0.492
* Data as numbers and percentages in parenthesis unless otherwise stated.
Braz J Infect Dis 2011; 15(4):370-376
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finitive antimicrobial treatment was 46.08 (95% CI 25.92-
66) in cases and 71.04 (95% CI 46.08-96.0) in controls 
(p = 0.111).
The crude mortality rate was 50.9% (27/53) in cases and 
13.2% (21/159) in controls (p < 0.001). The time elapsed 
from isolation of the causative pathogen in blood culture 
until death was statistically significant between cases (medi-
an 26 days, 95% CI 5.2-46.8) and controls (median 94 days, 
95% CI 28.5-159.5) (p < 0.001) (Figure 1). There was a trend 
to a longer length of hospital stay from hospital admission to 
death in cases (median 53 days, 95% CI 30.0-76.0) in com-
parison to controls (median 118 days, 95% CI 49.7-186.3) 
(p = 0.073) (Figure 2).
The results of this study show that the administration 
of different families of antimicrobials during a period of 90 
days before the episode of bloodstream infection was the 
only risk factor for the identification of ESBL-producing 
E. coli or K. pneumoniae in blood culture. In addition, those 
patients that previously received more than two different 
families of antimicrobials showed a risk of at least 2.5 times 
higher than patients treated with fewer antimicrobial fami-
lies. Although the model showed good calibration, it had 
moderate discriminatory power [area under the ROC curve 
was 0.718 (95% CI 0.58-0.85, p = 0.005)].
Bloodstream infection caused by ESBL-producing 
E. coli or K. pneumoniae was not associated with previ-
ous antimicrobial treatment, use of individual agents of 
each antimicrobial family or a particular antimicrobial 
agent. Previous use of antimicrobial treatment has been one 
of the factors more extensively related to identification of 
ESBL-producing E. coli and K. pneumoniae in patients in-
fected and/or colonized by these microorganisms.7-9 Almost 
half of the case patients received delayed adequate antimi- 
crobial treatment. Not considering the possibility of an ESBL- 
producing microorganisms isolation could be the cause of 
this delay.
Data reported in the literature regarding risk factors for 
ESBL-producing organisms are heterogeneous due, in part, 
to the inclusion of both infected and colonized patients in 
the different series. In order to minimize this bias, only pa-
tients with documented bloodstream infection were includ-
ed in our study.
In contrast to our results, isolation of ESBL-producing 
strains in most studies has been associated with the use of 
specific types and classes of antimicrobial agents. Previ-
ous β-lactam antibiotics, mainly cephalosporins, have been 
identified as predictive factors for infection with ESBL-pro-
ducing E. coli or K. pneumoniae.10-12
In a retrospective analysis of 2,172 episodes of health-
care-associated bacteremia diagnosed during a 3-year 
period in a teaching hospital, previous use of cephalospor-
ins and carbapenems were significantly associated with 
ESBL-producing E. coli or Klebsiella spp.13 In a prospective 
case-control study of bacteremia caused by E. coli, previous 
use of oxyimino-β-lactams or fluoroquinolones were inde-
pendent risk factors among hospitalized patients for ESBL-
producing strains.14 Other studies, however, have found an 
association between previous exposure to antimicrobials in 
general and identification of ESBL-producing strains in pa-
tients with bacteremia caused by K. pneumoniae.15
In a retrospective case-control study in patients with 
K. pneumoniae bacteremia, for the addition of each antimi-
crobial agent, an increase of 1.55 in the risk of ESBL-produc-
ing K. pneumoniae strains was observed.16 
Although a large number of studies included in their 
objectives to assess the association between use of antibi-
otics and the emergence of resistance, the systems used to 
define the prior use of antimicrobials have not been properly 
Figure 1: Actuarial curve for survival from isolation of  
ESBL-producing E. coli or K. pneumoniae to death.
Figure 2: Actuarial curve for survival from hospital 
admission to death.
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described. Thus, the selection of one or other method of 
categorization can lead to the identification of different risk 
factors.17 For this reason, it is important to clarify these issues 
for the design of strategies aimed at reducing resistances.
Other variables associated with the identification of 
ESBL-producing strains in patients with bloodstream in-
fection reported in the literature are the patient’s age,15 
severe underlying diseases,13 renal transplantation,13 pre-
vious admission to the ICU,18 duration of hospitalization 
before bacteremia,19 prior exposure to urinary cath-
eters,10,14,16 invasive procedure within the previous 72 
hours,16 and the nosocomial origin of bacteremia.10
In a systematic review of studies evaluating the associa-
tion between inappropriate antibiotic therapy and mortal-
ity among bacteremic patients, measurement of severity of 
illness without specified the time at which it was measured 
was considered a source of methodological heterogeneity 
that may explain conflicting findings.20 Our study adhered 
to key recommendations of this review to reduce the ef-
fect of potential confounders by assessing severity of illness 
through the SAPS II score.21
The present study was designed as a retrospective case-
control study in which controls were matched to cases 
according to three variables, including species of infect-
ing organisms, patient’s age and SAPS II score in the 
24-48h before blood sampling for culture. Limitations 
of the study include the retrospective design, the sample 
size and the lack of inclusion of the bacteremic focus as 
a selection criterion for controls. In order to overcome 
this limitation, controls were matched in a 3:1 ratio to 
case patients.
The identification of patients with risk factors for 
ESBL-producing organisms is essential to target adequate 
early empirical antimicrobial therapy. Previous use of more 
than two different families of antimicrobials in patients 
with bloodstream infection caused by E. coli or K. pneu-
moniae increased the risk for ESBL-producing strains. This 
variable should be considered as a potential risk factor for 
bacteremia by ESBL-producing organisms.
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